Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Journal of Parasitology Research |
Online Access: | http://dx.doi.org/10.1155/2011/656523 |
id |
doaj-4621a95064294577983d23439ec643c3 |
---|---|
record_format |
Article |
spelling |
doaj-4621a95064294577983d23439ec643c32020-11-25T00:01:27ZengHindawi LimitedJournal of Parasitology Research2090-00232090-00312011-01-01201110.1155/2011/656523656523Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous LeishmaniasisPouran Layegh0Omid Rajabi1Mahmoud Reza Jafari2Parisa Emamgholi Tabar Malekshah3Toktam Moghiman4Hami Ashraf5Roshanak Salari6Research Center for Skin Diseases & Cutaneous Leishmaniasis, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Medicinal Chemistry, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Pharmaceutics, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Dermatology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IranDepartment of Dermatology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IranMashhad University of Medical Sciences, Mashhad, IranBuali (Avicenna) Research Institute, Mashhad University of Medical Sciences, Mashhad, IranBackground. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared with intralesional glucantime in the treatment of cutaneous leishmaniasis. Methods. From 110 patients, the randomly selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3–7 drops twice daily, according to the lesion's size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2 mL once a week for the same period. The clinical responses and side effects of both groups were evaluated weekly during the treatment course. Results. Per-protocol analysis showed no statistically significant difference between the two groups (𝑃=0.317, 95% confidence interval (CI)=1.610 (0.632–4.101)). Moreover, after intention-to-treat analysis, the same results were seen (𝑃=0.650, 95% CI=0.1.91 (0.560–2.530)). Serious post treatment side effects were not observed in either group. Conclusions. Topical liposomal amphotericin B has the same efficacy as intralesional glucantime in the treatment of cutaneous leishmaniasis.http://dx.doi.org/10.1155/2011/656523 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pouran Layegh Omid Rajabi Mahmoud Reza Jafari Parisa Emamgholi Tabar Malekshah Toktam Moghiman Hami Ashraf Roshanak Salari |
spellingShingle |
Pouran Layegh Omid Rajabi Mahmoud Reza Jafari Parisa Emamgholi Tabar Malekshah Toktam Moghiman Hami Ashraf Roshanak Salari Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis Journal of Parasitology Research |
author_facet |
Pouran Layegh Omid Rajabi Mahmoud Reza Jafari Parisa Emamgholi Tabar Malekshah Toktam Moghiman Hami Ashraf Roshanak Salari |
author_sort |
Pouran Layegh |
title |
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis |
title_short |
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis |
title_full |
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis |
title_fullStr |
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis |
title_full_unstemmed |
Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis |
title_sort |
efficacy of topical liposomal amphotericin b versus intralesional meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis |
publisher |
Hindawi Limited |
series |
Journal of Parasitology Research |
issn |
2090-0023 2090-0031 |
publishDate |
2011-01-01 |
description |
Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared with intralesional glucantime in the treatment of cutaneous leishmaniasis. Methods. From 110 patients, the randomly selected 50 received a topical liposomal formulation of amphotericin B into each lesion, 3–7 drops twice daily, according to the lesion's size and for 8 weeks. The other group of 60 patients received intralesional glucantime injection of 1-2 mL once a week for the same period. The clinical responses and side effects of both groups were evaluated weekly during the treatment course. Results. Per-protocol analysis showed no statistically significant difference between the two
groups (𝑃=0.317, 95% confidence interval (CI)=1.610 (0.632–4.101)). Moreover, after intention-to-treat analysis, the same results were seen (𝑃=0.650, 95% CI=0.1.91 (0.560–2.530)). Serious post treatment side effects were not observed in either group. Conclusions. Topical liposomal amphotericin B has the same efficacy as intralesional glucantime in the treatment of cutaneous leishmaniasis. |
url |
http://dx.doi.org/10.1155/2011/656523 |
work_keys_str_mv |
AT pouranlayegh efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis AT omidrajabi efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis AT mahmoudrezajafari efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis AT parisaemamgholitabarmalekshah efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis AT toktammoghiman efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis AT hamiashraf efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis AT roshanaksalari efficacyoftopicalliposomalamphotericinbversusintralesionalmeglumineantimoniateglucantimeinthetreatmentofcutaneousleishmaniasis |
_version_ |
1725441960789934080 |